{"id":"W2127680641","doi":"10.1158/1078-0432.ccr-05-2255","title":"Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sudbury Regional Hospital","funders":"","keywords":"Medicine; Internal medicine; Mucositis; Neutropenia; Cyclophosphamide; Chemotherapy; Gastroenterology; Vinblastine; Regimen; Surgery; Clinical endpoint; Performance status; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002048036,0.001639002,0.001798754,0.0003206573,0.0003808886,0.0008174524,0.0008294042,0.001622924,0.00386635],"category_scores_gemma":[0.001274937,0.0003290228,0.0009415159,0.0003508777,0.001024502,0.0005318282,0.0002961089,0.002595804,0.0008371238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006238608,"about_ca_system_score_gemma":0.001538028,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004590212,"about_ca_topic_score_gemma":0.0007845505,"domain_scores_codex":[0.9994575,0.0002932038,0.00004056708,0.00006949273,0.0000448588,0.00009429232],"domain_scores_gemma":[0.9986421,0.0003551729,0.0003150449,0.00007664349,0.00007840912,0.0005325529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6857301,0.1144175,0.01215735,0.001933568,0.001929705,0.0004794571,0.0002938667,0.005586201,0.04314559,0.0006603408,0.009953183,0.1237132],"study_design_scores_gemma":[0.6569959,0.3220448,0.01082612,0.00006637722,0.0003312092,0.0003887205,0.00003192769,0.00154621,0.004736346,0.0001466222,0.002864252,0.00002148698],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819245,0.004682333,0.001409839,0.0008934109,0.0002010856,0.005819371,0.001325975,0.0001448201,0.003598551],"genre_scores_gemma":[0.9777253,0.003241768,0.003970267,0.001181267,0.0003455244,0.006438961,0.004528194,0.00002322925,0.002545524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00386635,"threshold_uncertainty_score":0.01293421,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07054438524096894,"score_gpt":0.4518263761429414,"score_spread":0.3812819909019725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}